Walleye Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Walleye Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,968	Closed	-$420K	–	2562
2022 Q1	$420K	Buy	+200,968	New	+$557K	0.01%	1104
2021 Q2	–	Sell	-17,400	Closed	-$102K	–	1444
2021 Q1	$102K	Buy	+17,400	New	+$120K	0.01%	1034

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's LXRX Position: Q2 2022 in Review

Walleye Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2022, closing a stake of 200,968 shares — an estimated $420K sold.

Walleye Capital first reported a position in LXRX in Q1 2021 and held it in 2 quarters. The position peaked at $420K in Q1 2022. 86 funds tracked by Wall St. Rank hold LXRX as of Q2 2022.

Walleye Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 200,968 Lexicon Pharmaceuticals shares in Q2 2022, an estimated $420K.
Walleye Capital first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 2 quarters.
Walleye Capital's Lexicon Pharmaceuticals position peaked at $420K in Q1 2022.
86 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.